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ABSTRACT: Structures of integral membrane receptors provide valuable models for drug−receptor
interactions across many important classes of drug targets and have become much more widely available in
recent years. However, it remains to be determined to what extent these images are relevant to human
receptors in their biological context and how subtle issues such as subtype selectivity can be informed by
them. The high precision structural modiﬁcations enabled by unnatural amino acid mutagenesis on
mammalian receptors expressed in vertebrate cells allow detailed tests of predictions from structural
studies. Using the Cys-loop superfamily of ligand-gated ion channels, we show that functional studies lead
to detailed binding models that, at times, are signiﬁcantly at odds with the structural studies on related
invertebrate proteins. Importantly, broad variations in binding interactions are seen for very closely related
receptor subtypes and for varying drugs at a given binding site. These studies highlight the essential
interplay between structural studies and functional studies that can guide eﬀorts to develop new
pharmaceuticals.
1. INTRODUCTION
Recent years have seen a remarkable increase in our knowledge
of the structures of integral membrane proteins such as ion
channels, transporters, and GPCRs. Of course, these proteins
are major targets of the pharmaceutical industry, and the
expectation is that structural information will provide valuable
guidance to eﬀorts to develop new drugs. The structural
insights do, however, come with some caveats. Often the
protein is of bacterial origin or from some other, non-
mammalian source. The structures are frequently of fragments
or homologues of the true receptor, and/or they are heavily
modiﬁed to enable crystallization. Even in the rare case of an
unmodiﬁed mammalian receptor succumbing to crystallo-
graphic study with a relevant drug bound, the snapshot
provided by X-ray crystallography may be ambiguous with
regard to the state of the receptor being imaged and may be
opaque with regard to the signaling process the receptor
initiates. Also, a crucial issue in drug development (the
targeting of small molecules to speciﬁc subtypes of a family
of very closely related receptors) is not well addressed by a
single image. To be clear, the structures are extraordinarily
valuable, but they do not tell the whole story.
In principle, functional studies of intact mammalian receptors
can provide powerful tests of predictions based on structural
studies. However, often the tools are too crude to be
convincing. How does one establish that a particular hydrogen
bond is essential to receptor function? Pharmacology (varying
the drug) provides one eﬀective strategy. Mutagenesis (varying
the protein) complements the pharmacology, and the two in
combination can produce compelling insights. Still, it is often
diﬃcult to provide convincing evidence for a particular
noncovalent interaction and even more diﬃcult to provide a
measure of the strength of a particular noncovalent interaction.
Over the past 20 years our group has conducted in vivo
studies on receptors and ion channels, employing unnatural
amino acid mutagenesis to gain chemical-scale insights into
receptor binding sites.1−3 The advantage of the unnatural
amino acid methodology is that it allows the protein scientist to
exercise the same level of precision in structurally modifying the
protein that the medicinal chemist routinely applies to the small
molecule. These studies can provide evidence for (or against)
proposed ligand binding interactions and in favorable cases can
provide semiquantitative information on noncovalent inter-
actions. In addition, variations in binding among receptor
subtypes, a common and especially important theme in
receptor pharmacology, can be probed by this approach.
Here we summarize a large number of studies that have
evaluated drug−receptor interactions across a family of related
receptors, the Cys-loop ligand-gated ion channels. Our focus is
on the region of the agonist binding site, leaving a discussion of
the fascinating process of channel gating for another time. The
more recent work is certainly guided/inspired by the structural
studies. In many cases, key noncovalent interactions seen in
crystal structures are found to be functionally important.
However, we also see instances in which a prediction from the
structure is not supported by functional studies, and cases
where a very diﬀerent model is indicated. Our results suggest
that variations abound in ligand binding modes, even among
very closely related receptors, and that extrapolations from
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model structures to the mammalian proteins of interest should
be made with caution.
2. Cys-LOOP RECEPTORS
2.1. Background and Biological Function. Fast synaptic
transmission relies on membrane proteins that couple exquisite
molecular recognition of neurotransmitters to microsecond
allosteric transitions, permitting ion passage across the
postsynaptic membrane. Ligand-gated ion channels (LGICs)
accomplish this feat,4 with central players being the pentameric
receptors of the Cys-loop superfamily.5,6 Other LGICs include
the trimeric P2X receptors and the tetrameric ionotropic
glutamate receptors. These include excitatory, cation-selective
channels that are opened by the ligands acetylcholine (the
nicotinic acetylcholine receptors, nAChRs) and serotonin (5-
HT3 receptors), along with inhibitory, anion-selective channels
that are opened by γ-aminobutyric acid (GABA) and by glycine.
As critical mediators of neurotransmission, Cys-loop receptor
dysfunction unsurprisingly associates with disease,7,8 including
myasthenic syndromes, epilepsy, schizophrenia, Parkinson’s
disease, and Alzheimer’s disease. Currently prescribed ther-
apeutics targeting Cys-loop receptors include muscle relaxants,
smoking cessation aids, antiemetics, and anxiolytics.
2.2. Structural Studies Related to Cys-Loop Recep-
tors. The global architecture of Cys-loop receptors is well
established, based on cryo-EM studies of the Torpedo ray
nAChR,9 X-ray structures of the related prokaryotic receptors
ELIC and GLIC,10−12 and most recently the ﬁrst X-ray
structure of a true Cys-loop receptor, the anion-selective
channel GluCl from C. elegans13 (Figure 1A). Receptors are
pentamers, with each subunit containing four membrane-
spanning α-helices and a large, primarily β-sheet, N-terminal
extracellular domain. The ﬁve subunits arrange pseudo-
symmetrically around a pore lined by the second trans-
membrane helix, and ligand-binding sites are found at subunit
interfaces in the extracellular domain.
Our structural understanding of ligand binding to nAChRs in
particular, and to some extent Cys-loop receptors in general,
has been greatly enhanced by structures of invertebrate
acetylcholine binding proteins (AChBPs).14−17 These soluble
proteins have proven to be amenable to crystallization, and they
share structural homology and 20−25% sequence identity with
the nAChR extracellular domain. Each binding site comprises
six “loops” labeled A−F, with A−C forming the “principal face”
and D−F contributed by the adjacent subunit and forming the
“complementary face” (Figure 1B). The C loop is thought to be
mobile in nAChRs, and it wraps over the ligand in the active
receptor.
AChBP structures reveal a conﬂuence of aromatic residues
that are highly conserved in nAChRs and that are arranged into
an “aromatic box” (Figure 1C). These aromatics have been
named by the loop on which they reside: TyrA, TrpB, TyrC1,
TyrC2, and TrpD. Other Cys-loop receptor binding sites are
also rich in Phe, Tyr, and Trp, often seen at these conserved
aromatic box sites. AChBP is believed to approximate an
agonist-bound conformation of the binding site, corresponding
to an active or a desensitized state. Over 60 AChBP structures
have been reported, many in complex with pharmacologically
relevant ligands.16 Additionally, AChBPs have been modiﬁed to
more closely mimic the extracellular domain residues and
binding sites of the α7 nAChR extracellular domain18,19 and of
the 5-HT3 receptor binding site.
20 It should be appreciated,
however, that AChBP is merely a homologue of the nAChR
extracellular domain and further that ligand binding does not
gate a transmembrane channel.
Importantly, all these structural studies conﬁrmed con-
clusions that were reached on the basis of prior biochemical
studies, including an interfacial binding site, the loop regions
A−F, the preponderance of aromatic amino acids at the agonist
binding site, and other features. This engenders conﬁdence that
these structures, including those of proteins that are only
obliquely related to the mammalian receptors, are highly
relevant. Key questions remain, however. Which structural
features have functional signiﬁcance? How does ligand binding
lead to channel gating? How is selectivity achieved among very
closely related receptors? Our view is that functional studies,
guided by these structural results, provide the best route to
answering these and other key questions.
3. UNNATURAL AMINO ACID MUTAGENESIS
STRATEGIES TO PROBE BINDING INTERACTIONS
Ligand binding is mediated by various noncovalent interactions,
such as hydrogen bonds, ion pairs, and cation−π interactions.
Establishing the importance of such weak interactions can be
challenging using conventional methods. As such, we have
developed and applied a number of strategies based on
unnatural amino acids that can probe noncovalent interactions
with high precision.1−3 The key is that unnatural amino acid
Figure 1. (A) Cryo-EM structure of the Torpedo nAChR (PDB 2BG9). (B) Acetylcholine binding protein (AChBP) from Lymnaea stagnalis, with
loops colored that form the principal (A−C) and complementary (D−F) faces of the binding site (PDB code 1UW6). (C) Aromatic box of the
AChBP binding site comprising Trp and Tyr residues conserved across nAChRs.
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mutagenesis allows subtle and systematic changes to a potential
binding interaction, thus producing convincing evidence for its
signiﬁcance (or insigniﬁcance). Here we describe general
strategies that we have employed across the entire Cys-loop
receptor family and to many other proteins. All studies involved
receptors expressed in Xenopus oocytes, and our primary
characterization was through a dose−response curve generated
from two electrode-voltage clamp recordings of ion channel
activity.
Hydrogen bonding is universally employed in drug−receptor
interactions. When the protein side chain is involved, both
conventional and unnatural amino acid mutagenesis provide
strategies to evaluate the interaction, although the unnatural
amino acid approach can provide more compelling evidence.
However, often it is the protein backbone that is the hydrogen
bond partner for the drug, and such an interaction cannot be
probed by conventional mutagenesis. Fortunately, unnatural
amino acid mutagenesis provides a powerful approach. Not
only can a large, diverse range of unnatural α-amino acids be
incorporated by our methodology, but α-hydroxy acids can also
be employed. As shown in Figure 2A, this amide-to-ester
mutagenesis allows us to probe both hydrogen bond donor and
acceptor roles for the protein backbone. Interestingly, both
model studies21,22 and our own experience have shown that the
two perturbations (removing the backbone NH and attenuating
the backbone CO) can have comparable impacts, and we have
used both extensively.
Ion pairs involving Asp and Glu are conventionally probed
with Asn and Gln, respectively, but unnatural amino acid
mutagenesis provides more subtle probes. For example,
nitrohomoalanine (Nha, Figure 2B) is isosteric and isoelec-
tronic to Glu but lacks the negative charge.23 Also, structures
like Akp provide alternatives to Asn and Gln.
Another noncovalent interaction that is important in many
drug−receptor interactions, and which was long anticipated to
be important in nicotinic receptors,24 is the cation−π
interaction.25−27 The primary attraction in a cation−π
interaction is between a positive charge (typically on the
drug) and the negative electrostatic potential associated with
the face of the aromatic rings of Phe, Tyr, and Trp. This
attraction can be systematically modulated by progressive
ﬂuorination of the aromatic ring (Figure 2C), as ﬂuorines
withdraw electron density from the ring. This ﬂuorination
strategy has been used to establish cation−π interactions for
dozens of drug−receptor pairs,27 and it will ﬁgure prominently
in our evaluation of Cys-loop receptors.
It should be noted from the start that, technically, the studies
described here do not evaluate whether a particular non-
covalent interaction is present or not. We are probing whether
a particular interaction is functionally signif icant. That is, we
determine whether perturbing or in some cases removing a
noncovalent interaction impacts receptor function in a
meaningful way. Our typical measure of function is EC50, a
composite measurement that reﬂects both agonist binding and
receptor gating and, as such, involves multiple equilibria. As
discussed in detail elsewhere,28 when mutating residues that are
expected to be in direct contact with the agonist, it is clear that
we are perturbing a noncovalent binding interaction, although
there may be ambiguity about which particular equilibrium is
being perturbed by the change in binding. And of course in any
structure−function study, the structure of the receptor must be
changed, and it is possible that unanticipated, large structural
changes are induced by a mutation. Without structural
corroboration, this cannot be ruled out, but we would argue
that the very subtle mutations enabled by unnatural amino acid
mutagenesis make such a complication less likely.
4. NICOTINIC ACETYLCHOLINE RECEPTORS (nAChRs)
nAChRs are the most thoroughly studied Cys-loop receptors
and will be the primary focus of this review. Subunits are
primarily classiﬁed as α (10 variants) or β (4 variants), with the
former contributing the principal face of the agonist binding
site and the latter generally contributing the complementary
face. Dozens of receptors subtypes, formed by diﬀering
combinations of α and β subunits, have been established to
be active in humans.7,8 In the brain, homomeric α7 receptors
and receptors containing α4 and β2 subunits are the dominant
subtypes expressed.29 The receptor of the neuromuscular
junction, a close homologue of Torpedo electroplax nAChR, has
a unique subunit composition of (α1)2β1γδ (fetal form; in
adults the ε subunit substitutes for γ), with binding sites found
at α/γ and α/δ interfaces. Here we consider ligand binding to
the α4β2, α4β4, and α7 neuronal receptors and to the muscle-
type receptor.
4.1. A Model of nAChR Ligand Binding Suggested by
AChBP Structures. Over 40 years ago it was recognized that
nAChR agonists share a pharmacophore comprising a cationic
nitrogen separated by approximately 4−6 Å from a hydrogen
bond-accepting group.30 A subset of nicotinic agonists is shown
in Figure 3, highlighting these common structural features.
Figure 2. (A) α-Hydroxy acid strategy to evaluate backbone hydrogen
bonding. The backbone NH group is removed and the backbone CO
becomes a weaker hydrogen bond acceptor (dashed line). (B) Asp and
Glu analogues. (C) Trp and Phe analogues.
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Over the past decade, AChBP structures in complex with
nicotinic agonists (including carbamylcholine, nicotine, and
epibatidine) have suggested binding partners for these groups
at the receptor.15,31 AChBP structures from diﬀerent organisms
and in complex with diﬀerent agonists all show similar side
chain conformations at the binding site. In all of these
structures, the cationic group of the agonist is oriented toward
the principal face of the binding site, and three potential
noncovalent interactions are evident (Figure 4): (1) a cation−π
interaction with TrpB; (2) a cation−π interaction with TyrC2;
(3) a hydrogen bond between the agonist N+H group (for
agonists with this moiety) and the TrpB backbone CO. The
hydrogen bond acceptor of the agonist faces the comple-
mentary subunit. In AChBP structures the hydrogen bond
donor is a water molecule, which in turn binds to the protein,
establishing a network of three hydrogen bonding interactions:
(4) agonist hydrogen bond acceptor to water; (5) the backbone
NH of a conserved Leu on loop E (“LeuE”) to water; (6) the
backbone CO of a conserved Asn on loop E (“AsnE”) to water.
We will refer to noncovalent interactions by the numbers of
Figures 4 and 5 throughout.
These interactions form a binding model for these agonists
with AChBP, interactions that can be tested at the actual
nAChRs of interest. AChBP pharmacology diﬀers from that of
nAChRs (it is most similar to that of the α7 receptor),16 and of
course, AChBPs serve a distinct functional role and do not gate
a channel. Further, while AChBP structures with varying
ligands bound generally show similar conformations, pharma-
cology varies considerably across nAChRs. Notably, nicotine is
potent at the α4β2 receptor but not at muscle-type or α7
receptors, and in general the α7 receptor displays unique
pharmacology from the other neuronal nAChRs.32
4.2. Ligand Binding to the α4β2 Neuronal nAChR.
α4β2 receptors are one of the dominant nAChR subtypes
expressed in the brain and can assemble in two diﬀerent
stoichiometries: (α4)2(β2)3 and (α4)3(β2)2. This receptor
binds nicotine with high aﬃnity and is established to play a key
role in nicotine dependence from smoking. Consequently, it
has been targeted by smoking cessation therapeutics, including
the compounds varenicline33 and cytisine,34 which are
marketed commercially as Chantix and Tabex, respectively.
We have evaluated ligand binding interactions for the native
agonist acetylcholine, for nicotine, and for these two smoking
cessation agents at both stoichiometries of this receptor (Tables
1 and 2).
All agonists, at both stoichiometries, form a cation−π
interaction with TrpB (Table 1, interaction 1), as evidenced
by responses to ﬂuorotryptophan mutations.35,36 A plot of EC50
vs the cation−π binding ability of the side chain shows a
compelling correlation. Single channel studies conﬁrm that the
perturbation to EC50 results from a change in the ligand
binding step of receptor activation.36
Notably, mutagenesis does not corroborate the cation−π
interaction to TyrC2 suggested by AChBP structures
(interaction 2): this site accepts the highly deactivating CN-
Phe mutation with no shift in receptor EC50 for both ACh and
for nicotine.36 At other Cys-loop receptors we have been able
to see evidence for cation−π interactions to two aromatics at
the same time in a given receptor (see below), so a signiﬁcant
cation−π interaction to TyrC2 could have been detected. The
TrpB cation−π interaction provides critical experimental
evidence for the positioning of these agonists in the binding
site, but the TyrC2 data suggest that we should expect
diﬀerences between the AChBP binding site and that of the
α4β2 receptor.
The remaining aromatic box residues of the principal face,
TyrA and TyrC1, were also evaluated for cation−π interactions
by unnatural amino acid mutagenesis. No such interaction was
found at TyrA. TyrC1, well-known to have a critical role in
nAChR gating,37,38 was extremely sensitive to substitution,
preventing extensive evaluation. The role of a hydrogen bond
donor appears to be especially critical at this site: both Phe
(which removes the side chain −OH) and MeO-Phe (which
retains hydrogen bond acceptor but not donor ability)
produced EC50 shifts of approximately 100-fold for acetylcho-
line.36
We see strong evidence for hydrogen bonds between agonist
N+H groups and the backbone CO of TrpB (interaction 3).
Figure 3. Nicotinic agonists. Cationic nitrogen (blue) and hydrogen
bond acceptor (red) correspond to the nicotinic pharmacophore.
Figure 4. Nicotinic agonist binding interactions suggested by AChBP
and key binding site residues. Shown is a structure of AChBP in
complex with nicotine (PDB code 1UW6). Numbered interactions are
discussed in the text. Explicit hydrogens are displayed for hydrogen
bonding groups. AsnE and LeuE are conserved in all nAChRs but are
Leu and Met, respectively, in the AChBP structure shown.
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Converting the residue i + 1 to TrpB to its α-hydroxy analogue
weakens the hydrogen bond acceptor strength of this CO. This
mutation produced a 19-fold shift in EC50 for nicotine at both
receptor stoichiometries but critically had no eﬀect on the EC50
for ACh (which cannot form this interaction).35,36
We have also probed the water-mediated hydrogen bonds
seen in AChBP by converting LeuE to its α-hydroxy analogue,
thus disrupting interaction 5.39 Signiﬁcant impacts were seen
for ACh and nicotine (Table 2). To convincingly assign an
interaction between the LeuE backbone NH and the agonist
hydrogen bond acceptor group, we performed a nontraditional
“mutant cycle analysis” involving both the receptor and the
agonist. We prepared and evaluated the nicotine analogue S-
MPP, which replaces the pyridine ring with a phenyl group
(Figure 3). We evaluated the additivity of the LeuE α-hydroxy
mutation and the nicotine-to-(S-MPP) “mutation”. The
mutations were strongly nonadditive, producing a 2.6 kcal/
mol coupling energy. This clearly establishes a strong
interaction between the agonist hydrogen bond acceptor and
the LeuE backbone NH. Unfortunately, eﬀorts to probe the
other component of the water-mediated hydrogen bonding
network (interaction 6) by modulating the AsnE backbone CO
were unsuccessful for technical reasons (but see results below
from other nAChRs).
For the three interactions identiﬁed above (1, 3, and 5), we
see variations among diﬀerent agonists and between the two
receptor stoichiometries. Cation−π interactions to TrpB
(interaction 1) are seen for all agonists tested, but the strength
of this interaction varies. As discussed elsewhere,28 we consider
the EC50 ratio of the tetraﬂuorotryptophan (F4-Trp) mutant to
wild type Trp as a measure of cation−π strength. The cation−π
eﬀect ranges from a maximum of 540-fold for ACh at the
Table 1. EC50 Shifts for Mutations Probing Ligand−
Receptor Cation−π Interactions in Cys-Loop Receptorsc
aF4Trp data unavailable; value is an extrapolation of the ﬁt of EC50
shifts for other deactivated Trp analogues. bRatio of F4Trp/Trp IC50
values for these antagonists. cValues are EC50 fold shifts for F4Trp
(Trp sites) or F3Phe (Phe or Tyr sites) relative to wild type, and values
of >1 indicate a loss of function (increase in EC50 for the mutant).
Shading ranges from green (smallest value) to red (largest value), with
colors assigned to the logarithm of each value to emphasize diﬀerences
in free energy.
Table 2. EC50 Shifts for α-Hydroxy Acid Mutations Probing
Agonist−Receptor Hydrogen Bonds in nAChRsa
aFor TrpB CO and AsnE CO (probing interactions 3 and 6,
respectively), values are EC50 fold shift from wild type for the α-
hydroxy acid mutation i + 1 to the site of interest. For LeuE NH
(probing interaction 5), values are EC50 fold shift from wild type for α-
hydroxy leucine at the LeuE site. Values of >1 indicate a loss of
function (increase in EC50 for the mutant). Shading ranges from green
(smallest value) to red (largest value), with colors assigned to the
logarithm of each value to emphasize diﬀerences in free energy. ND =
not determined.
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(α4)3(β2)2 receptor, corresponding to 3.7 kcal/mol, to a
minimum shift of 16-fold, 1.6 kcal/mol, for varenicline at this
same stoichiometry (Table 1).
It is interesting that ACh, the only agonist evaluated with a
quaternary ammonium group, shows the strongest cation−π
interaction among this panel of agonists. Intrinsic cation−π
binding aﬃnity is greater for protonated amines than for
quaternary amines.40,41 The strong binding energy for ACh
suggests that the receptor has evolved to optimize the cation−π
interaction when binding its native agonist. Also, for agonists
such as nicotine it may not be possible to achieve a geometry
that is simultaneously optimal for both the hydrogen bond
interaction 3 and the cation−π interaction 1, and perhaps these
agonists sacriﬁce some cation−π binding ability to strengthen
the hydrogen bond.15,17,42
The interaction involving the agonist hydrogen bond
acceptor group and the LeuE backbone NH also varies across
the agonists assayed (Table 2). Notably, no interaction was
seen for varenicline at either receptor stoichiometry. Two
factors could account for this result. First, the hydrogen bond
acceptor group and positively charged nitrogen have a greater
separation in varenicline than in the other agonists investigated,
raising the possibility that the geometry is no longer
appropriate for this hydrogen bond, although the interaction
is present in a structure of AChBP in complex with
varenicline.42 The second possibility is that the agonist
hydrogen bond acceptor could indeed be appropriately
positioned, but the interaction is much weaker than for the
other agonists considered, and thus perturbation of this
hydrogen bond has no impact on our functional assay. Indeed,
varenicline is expected to be a much poorer hydrogen bond
acceptor than nicotine. It is known that pKa can be a reliable
predictor of hydrogen bonding strength when considering
closely related systems. On this basis, the quinoxaline N of
varenicline (pKa = 0.8) is expected to be a signiﬁcantly weaker
hydrogen bond acceptor than the pyridine N of nicotine (pKa =
5.2).
In contrast, evidence for an unusually strong interaction was
seen for cytisine: this agonist had the largest shift for the LeuE
mutation at each receptor stoichiometry, with a remarkable 62-
fold shift seen for (α4)2(β2)3. The hydrogen bond acceptor in
cytisine is an amide oxygen, which is well-established to be a
stronger hydrogen bond acceptor than a heterocyclic N such as
is seen in nicotine or varenicline. Data like these indicate that
the unnatural amino acid methodology not only can identify
key interactions but also can give semiquantitative guidance as
to the strength of a given interaction.
4.3. Ligand Binding to the α4β4 Neuronal nAChR. The
α4β4 neuronal nAChR presents a diﬀerent complementary face
to the binding site than does α4β2, resulting in a distinct
pharmacology.43 As in all nAChRs, residues of the aromatic box
are identical, suggesting that interaction with the comple-
mentary face may play a greater role in establishing subtype
speciﬁcity. Nevertheless, the side chains at the positions
corresponding to LeuE and AsnE are very highly conserved.
The same agonist−receptor interactions probed in the α4β2
receptor were also tested in the (α4)2(β4)3 stoichiometry of
this receptor.
For α4β4, we found that ACh and nicotine bind the receptor
using a cation−π interaction with TrpB (interaction 1), with
EC50 shifts for TrpB mutants suggesting similar interaction
strengths as in the (α4)2(β2)3 receptor (Table 1). Again, no
cation−π interaction to TyrC2 (interaction 2) was seen. Also
suggesting similar interactions with the α4 residues forming the
binding site’s principal face, we observe a hydrogen bond
between nicotine’s N+H and the TrpB backbone CO
(interaction 3). Other aromatic residues of the principal face
(TyrA, TyrC1) also appear to play a similar role in this receptor
as in α4β2.44
Interesting contrasts to α4β2 were seen at the comple-
mentary (β4) face. The mutation to the LeuE NH (interaction
5) produced only small EC50 shifts, 2- to 3-fold smaller for
ACh, nicotine, and epibatidine than in α4β2 and at the margin
of being detectable in our assay (Table 2). This interaction is
viable for β4, however: with cytisine a 14-fold shift was
observed, though this is still 4-fold smaller than in
(α4)2(β2)3.
45 In the α4β4 receptor we were able to probe
the AsnE backbone CO that additionally participates in the
water-mediated hydrogen bond to the agonist’s hydrogen bond
acceptor group in AChBPs (interaction 6). Here the α-hydroxy
mutation was applied i + 1 from this site to weaken the CO’s
hydrogen bond acceptor strength, as was done with hydrogen
bonding interaction 3 (Figure 2A). The mutation of AsnE did
not produce a meaningful eﬀect for a panel of agonists: ACh,
nicotine, epibatidine, varenicline, cytisine, and choline (EC50
shifts of 2-fold or less).
Overall, receptors with β4 rather than β2 at their
complementary face have reduced binding aﬃnities for a
variety of agonists.43 Our data suggest that a weaker interaction
involving the agonist hydrogen bond acceptor could contribute
to this eﬀect.
4.4. Ligand Binding to the α7 Neuronal nAChR. Several
features of the α7 nAChR distinguish it from the other principal
neuronal subtypes. It assembles as a homopentamer, and it is
phylogenetically more ancestral than the heteromeric receptor
subunits.46 In addition, α7 shows broad pharmacology and thus
an apparently less specialized binding site.32 Clearly this is a
diﬀerent sort of neuronal receptor, though again, the critical
aromatic box residues of the binding site are conserved.
Chimeras of the α7 extracellular domain and AChBP have been
crystallized, and they show remarkably similar binding sites to
other AChBP structures with regard to the aromatic residues,
LeuE, and AsnE.18,19
Consistent with this receptor’s distinct pharmacology, we
observe a distinct pattern of ligand binding interactions for α7.
TrpB is no longer the cation−π binding site for any of the
agonists evaluated (ACh, epibatidine, and varenicline). ACh
forms a cation−π interaction with TyrA (not seen in AChBPs,
where it is not structurally feasible), while epibatidine forms
cation−π interactions with both TyrA and TyrC2 (interaction
2), the stronger interaction being with TyrC2 (Table 1).28,44
Note that these ﬁndings for TyrA and TyrC2 are in stark
contrast to our data from all other nAChRs probed, for which
ﬂuorinated Phe and Tyr analogues revealed that side chain
electrostatics were relatively unimportant at these sites. Also in
contrast to the other nAChRs, wild type function of the TyrA
MeO-Phe mutant for ACh and varenicline reveals no
functionally meaningful hydrogen bond donor role for this
side chain, although a steric placeholder at the 4-position
appears to be important. Interestingly, some agonist-speciﬁc
behavior is observed at TyrC2: a steric placeholder at the 4-
position is important for ACh and epibatidine but not for
varenicline. In keeping with this receptor’s diﬀerent utilization
of principal face aromatic residues, the TrpB backbone CO
hydrogen bond to the agonist N+H (interaction 3) appears to
be weak in this receptor.
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Hydrogen bonds between the agonist hydrogen bond
acceptor and the AsnE backbone CO and LeuE backbone
NH groups on the binding site’s complementary face appear to
be weak or absent in the α7 nAChR (Table 2). Of the agonists
evaluated (ACh, epibatidine, and varenicline) we see a modest
shift (2.6-fold) only for epibatidine with the LeuE NH
mutation. The α7 receptor is also distinctive in that it is the
only one for which we have seen a meaningful interaction with
the Asn CO (interaction 6): a 4.3-fold shift is seen for
varenicline and only for varenicline. All other shifts were less
than 2-fold.28 It is possible that an agonist H-bond acceptor
group is not critical to binding and receptor activation for α7.
Some α7-speciﬁc agonists lack the canonical hydrogen bond
acceptor group. Notably, the structurally simple agonist
tetramethylammonium has equivalent potency and eﬃcacy to
ACh at this receptor, in contrast to its much weaker activity at
other nAChRs.32,47
4.5. Ligand Binding to the Muscle-Type nAChR. The
extensively characterized (α1)2β1γδ receptor found at the
neuromuscular junction is a “low aﬃnity” nAChR, especially
with regard to nicotine. Here TrpB is engaged in a cation−π
interaction (interaction 1) with acetylcholine.48 We note that
the muscle-type nAChR was actually the ﬁrst receptor to which
the unnatural amino acid methodology was applied, and the
cation−π interaction to TrpB was established a full 3 years
before the ﬁrst AChBP crystal structure revealed the aromatic
box motif.
There is also a cation−π interaction to TrpB with the
relatively potent agonist epibatidine, but for nicotine the
interaction is absent, in contrast to α4β2 and α4β4 (Table
1).48−50 Also in contrast to the α4-containing receptors, the
agonist N+H−TrpB CO hydrogen bond (interaction 3) appears
to be weak or absent for nicotine (Table 2). A modest
interaction is detected for epibatidine.50 Electrostatics of TyrA
and TyrC2 were unimportant when probing with ACh and with
nicotine.51 In another demonstration of ligand-speciﬁc behavior
at this receptor suggesting high specialization for its native
agonist, the ACh analogue NorACh, which lacks a single methyl
from its ammonium group, does not form a cation−π
interaction with TrpB.49
At the complementary face, the LeuE NH mutation
(interaction 5) has a dramatic eﬀect for ACh (29-fold), a
large eﬀect for nicotine (10-fold), and as expected, no eﬀect for
choline (Table 2). Interestingly, no shift was seen for
epibatidine.45 A distinct positioning of this agonist could
account for this observation, or alternatively it may reﬂect the
inherently weaker hydrogen bond acceptor strength of
epibatidine’s 2-chloropyridine N compared to nicotine’s
pyridine N (pKa of 0.5 vs 5.2, respectively).
52 No meaningful
shifts were detected for mutation of the AsnE CO group
(interaction 6),45 as generally seen at other nAChRs evaluated
(α4β4 and α7).
4.6. Interactions Shaping the nAChR Binding Site.
Diﬀerences in ligand binding behavior across nAChRs are well
established on the basis of pharmacology and have been
elucidated in detail by the unnatural amino acid mutagenesis
experiments described above. Such variety is not seen in the
dozens of AChBP structures, for which little variation is seen in
the relative positions of key residues. The aromatic box
residues, TrpB CO, LeuE NH, and AsnE CO, while completely
conserved, clearly engage diﬀerently with agonists in diﬀerent
receptor subtypes. Hence, peripheral interactions are likely
responsible for the diﬀerences we observe. We have primarily
probed peripheral interactions in the muscle-type receptor, and
we will use residue numbering corresponding to the muscle-
type receptor here. The relevant interactions are shown in
Figure 5.
One distinguishing feature of high aﬃnity nAChRs (such as
α4β2) is a loop B lysine four residues from TrpB of the ligand
binding site. The aligning residue is glycine in low aﬃnity
receptors such as muscle-type and α7. In AChBPs, the
backbone NH of this residue forms a hydrogen bond to the
backbone carbonyl i + 1 to TyrC2 on loop C (interaction 7,
Figure 5). Molecular dynamics simulations suggested that
mutations introducing a side chain to the loop B glycine site
favor formation of this hydrogen bond.53 We studied this
interaction in the muscle-type receptor and found that
mutation of this glycine (α1 G153) to lysine (as found in the
high aﬃnity α4 subunit) dramatically increases the potency of
nicotine at this receptor. The increase in aﬃnity occurs because
nicotine now forms a cation−π interaction with TrpB
(interaction 1) and a strong hydrogen bond with the TrpB
backbone CO (interaction 3).36,54 Such enhanced binding
aﬃnity has meaningful functional consequences in humans: a
single nucleotide polymorphism producing the α1 G153S
mutant induces a slow-channel myasthenic syndrome.55
The loop B Gly to Lys mutation in α7 also increases agonist
potency but notably does not induce a cation−π interaction
with TrpB; it instead strengthens the existing cation−π
interaction with TyrC2 for ACh and for Epi. Hence the
G153 mutation appears to eﬀect global repositioning of the
binding site, with diﬀerent ligand binding implications at each
receptor. The “reverse mutations” in the α4β2 receptor, Lys-to-
Gly or α-hydroxy acid mutations to the proposed loop B−
loop C backbone hydrogen bond (interaction 7), had only
Figure 5. Interactions shaping the nAChR binding site, as seen in
AChBP. AChBP structure and view of the binding site are identical to
those in Figure 4 (PDB code 1UW6). Residue numbering is for the
aligning residues of the muscle-type nAChR. Muscle-type nAChR side
chains labeled are identical in AChBP, with the exceptions of G153
and P197, which are Ser and Ala, respectively, in AChBP.
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small eﬀects, suggesting that additional factors may support the
high aﬃnity binding evolved at this receptor.35
A conserved aspartate on loop A (α1 D89 in the muscle-type
receptor) is also involved in shaping the nAChR binding site.
Structural studies of AChBPs revealed that this residue is
positioned behind TrpB, and several investigators have
proposed an essential role for the negative charge of this Asp
in agonist recognition.15,56 Unnatural amino acid mutagenesis
in the muscle-type receptor established that side chain charge is
not critical, as mutation to neutral analogues such as Nha and
Akp produced only modest eﬀects. Instead this Asp side chain
participates in a network of functionally signiﬁcant hydrogen
bonds. The hydrogen bond partners are two backbone NH
groups on loop B: those of TrpB and of Thr150 (TrpB + 1),
conﬁrmed by α-hydroxy acid mutagenesis of these backbone
groups (Figure 5, interactions 8 and 9).23
Another interesting motif of the nAChR agonist binding site
is the C loop vicinal disulﬁde of the principal binding face, the
deﬁning structural feature of nAChR α subunits. In most
AChBP structures, the vicinal disulﬁde participates in a type I β-
turn of the C loop involving a hydrogen bond between the
C193 backbone NH and the Y190 (TyrC1) backbone CO
(Figure 5, interaction 10). In the muscle-type receptor,
backbone mutations and mutant cycle analyses that probe
this hydrogen bond establish a strong interaction. These
include N-methylcysteine or α-hydroxycysteine mutants of
C193 or an α-hydroxy mutation to S191, which modulates the
Y190 CO. Interestingly, coupling to the Y190 CO is seen even
for the C193A side chain mutation, which preserves the C193
backbone but eliminates the vicinal disulﬁde. Thus, the primary
role of the nAChR α subunit vicinal disulﬁde appears to be
establishing an optimal position of the C193 backbone for
hydrogen bonding.57
Further studies of the α-hydroxy acid mutation at S191
established a speciﬁc role for the backbone NH as part of an
extended network of hydrogen bonds, connecting this NH to
the side chain of γD174/δD180, a conserved aspartate located
across the subunit interface on loop F (Figure 5, interaction
11).58 The γD174/δD180 aspartate had been shown in a classic
cross-linking experiment to lie near the vicinal disulﬁde.59
However, AChBP structures place γD174/δD180 quite far
from the agonist binding site, hence the imagery of Figure 5.
Instead, in AChBPs a diﬀerent loop F aspartate (aligning to
γE176/δE182 in the muscle receptor) forms a hydrogen bond
to the S191 NH (interaction 12). Conventional mutagenesis of
the γE176/δE182 side chain convincingly rules out a signiﬁcant
functional role for this residue. These ﬁndings thus establish a
substantive diﬀerence between AChBP and the full receptors.
The AChBP structures show a hydrogen bond corresponding
to 12 in Figure 5, but our studies of the full receptor rule out
interaction 12 and establish hydrogen bond 11 as playing an
important functional role instead, consistent with the earlier
biochemical studies. The long-range nature of the interactions
probed here was established by mutant cycles between the
termini of this hydrogen bonding network, the C193 NH and
the γD174/δD180 side chain (spanning interactions 10 and
11), which show a robust coupling energy (2.2 kcal/mol).57
Evidently, the characteristic vicinal disulﬁde of the α subunit
positions the S191 backbone NH for its intersubunit hydrogen
bond, via the carbonyl of TyrC1. Presumably hydrogen bond
11 forms in the ligand-bound, open channel and could
accompany C loop closure upon ligand binding. Such
rearrangements could underlie the well-known gating signiﬁ-
cance of TyrC1, a critical binding site residue of the aromatic
box.37,38
4.7. Overview of nAChR Studies. The family of nAChRs
represent a classic example of a common situation in drug
development: a family of closely related receptors that show
speciﬁc distribution patterns, diﬀering pharmacologies, and
distinct physiological roles. The large number of AChBP
structures with relevant small molecules bound have provided
invaluable insights into possible drug−receptor interactions.
However, very little variation is seen in protein structure, and so
little insight into subtype speciﬁcity can be obtained.
Using unnatural amino acid mutagenesis, we have seen
substantial variations in drug−receptor interactions in speciﬁc
receptor subtypes. The anticipated cation−π interaction is
evident in all receptors, with TrpB being the aromatic in most
subtypes. However, the α7 receptor rejects TrpB and instead
makes cation−π interactions to TyrA and TyrC2, with the
TyrA interaction being quite incompatible with AChBP
structures. This inconsistency arises despite the fact that
AChBP pharmacology is closest to that of α7 receptors.
Along with the cation−π interaction, the other key
component of the nicotinic pharmacophore is the hydrogen
bond acceptor, deﬁned by the CO of ACh and the pyridine N
of nicotine. Certainly, it was very diﬃcult to think about
probing this interaction before the AChBP structures, and a
novel model arose from them. Instead of a direct interaction
with the protein, the agonist binds to a water molecule. This
water in turn makes two hydrogen bonds to the protein
backbone of the complementary face. We ﬁnd many instances
where the LeuE NH is important for receptor function
(interaction 5), and using S-MPP as a probe, we have directly
linked the NH to the pyridine N of nicotine. There is some
variability that could be quite relevant to subtype speciﬁcity
issues, the α4β4 and α7 receptors showing weaker interactions.
Still, the LeuE NH interaction is clearly important in the family.
In contrast, we ﬁnd scant evidence for involvement of the AsnE
CO (interaction 6). We probed this interaction in 13 diﬀerent
drug−receptor combinations (Table 2). In 11 cases, we saw no
eﬀect; one produced a factor of 2 change, which we consider to
be borderline meaningful, and one produced a factor of 4. It
may well be that this interaction is not functionally relevant in
nAChRs, which raises an interesting possibility. If the water
molecule seen in AChBP structures was absent in nAChRs, the
LeuE NH can hydrogen-bond directly to the drug, and our
studies would show an important eﬀect of mutation. The AsnE
CO can only engage in a water-mediated hydrogen bond to the
drug, and if the water is absent, our studies would show
negligible/small eﬀects.
In other studies we have probed interactions that are
peripheral to the agonist binding site but that have strong
inﬂuences on receptor pharmacology. We characterized several
hydrogen bonding interactions that inﬂuence receptor function,
and in one case, we see a signiﬁcance diﬀerence between
predictions from the AChBP structures and the results of our
functional studies (interactions 11 and 12).
5. OTHER Cys-LOOP RECEPTORS
We have conducted numerous studies of other members of the
Cys-loop family. Here we highlight studies that parallel our
work on nAChRs.
5-HT3 receptors, serotonin receptors of the Cys-loop
superfamily, are most closely related to the nAChRs and also
are cation channels. 5-HT3 receptors are widely distributed in
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the CNS and also play important roles in the peripheral
nervous system. 5-HT3 receptor antagonists are currently
prescribed for management of nausea, vomiting, and irritable
bowel syndrome.60
As in nAChRs, the binding site of 5-HT3A receptors is rich in
aromatic residues. TrpB, TyrC2, and TrpD are conserved, and
additionally there are three tyrosines on loop E of the
complementary face: Y141 (aligning to the nAChR AsnE
site), Y143, and Y153 (aligning to the nAChR LeuE site). TyrA
is absent, but an additional glutamate is found on loop A. A
structure of a modiﬁed AChBP in complex with serotonin has
been reported. The construct contains four point mutations
that signiﬁcantly increase serotonin’s binding aﬃnity (by almost
40-fold),20 although some important binding residues are
absent.
Fluorination studies revealed a strong cation−π interaction
to TrpB in the 5-HT3A receptor (Table 1).
49 Cation−π
interactions involving TrpB were also detected for the
antagonists granisetron and ondansetron, suggesting a con-
served ligand binding mode that includes these actively
prescribed antiemetic compounds (marketed as Kytril and
Zofran, respectively).61 Tyrosines of the binding site were also
evaluated by unnatural amino acid mutagenesis, revealing a
critical hydrogen bond donor role for Y143 and a hydrogen
bond acceptor role for Y153 on loop E, both of which may
contribute to receptor gating.62
Serotonin analogues have clariﬁed receptor recognition of
this ligand’s polar groups (Figure 6). Interestingly, the
quaternary trimethylammonium analogue of serotonin (5-
HTQ) is as potent as serotonin at this receptor and also
forms a strong cation−π interaction with TrpB.49 Surprisingly,
1-oxo-5-hydroxytryptamine, in which an O replaces the indole
NH of serotonin, is equipotent to serotonin and a full agonist,
suggesting that this NH group is not essential to receptor
activation.63 In contrast, serotonin analogues that replace the 5-
hydroxy group, such as 5-ﬂuorotryptamine, have notably
reduced aﬃnities and low eﬃcacies.64 Conventional and
unnatural amino acid mutagenesis studies suggest that the
hydrogen bonding partner for the 5-hydroxy group is E129 on
loop A. At this site hydrogen bond acceptor ability, but not
charge, is critical to ligand binding.65
Hence, both key interactions for serotonin recognition by the
5-HT3A receptor apparently lie on the binding site’s primary
face: a cation−π interaction with TrpB and a hydrogen bond
between E129 (corresponding to TyrA) and the ligand’s 5-
hydroxy group. As in the nAChRs, a conserved aspartate lies
behind TrpB on loop A, and double mutant cycles between this
side chain (D124) and α-hydroxy acid mutations that delete the
backbone NH of either TrpB (W183) or L184 demonstrate
important hydrogen bonds between the Asp and these loop B
groups. Triple mutant cycles that expand to include the critical
E129 side chain demonstrate coupling between E129 and the
loop A−loop B interaction: any single mutation out of the three
decouples the other two. These results suggest a network of
coupled noncovalent interactions spanning from the TrpB
cation−π interaction with serotonin, through a series of
hydrogen bonds to loop A, to the proximal loop A side chain
E129, which makes a hydrogen bond to the agonist 5-hydroxy
group.66
Another receptor gated by serotonin is the C. elegans MOD-1
receptor, a chloride channel that is actually more closely related
to the GABA and glycine receptors. MOD-1 has the B and C2
side chains of the aromatic box transposed relative to 5-HT3A:
a Tyr is at the B site, and a Trp is at the C2 site. Remarkably,
the cation−π interaction for serotonin follows the tryptophan
to the C2 site (Table 1), providing a case of the same agonist
binding to two homologous binding sites with diﬀering
orientations.67 The switch could reﬂect the inherently stronger
cation−π binding ability of a Trp vs a Tyr.
GABAA and glycine receptors are anion-selective Cys-loop
receptors that mediate fast inhibitory neurotransmission in
adult neurons. These receptors have high homology and ∼30−
35% sequence identity to the crystallized C. elegans GluCl
receptor, making this structure a useful template for these
receptors’ binding sites.13 In the GluCl structure aromatic
residues are found at the nAChR aromatic box A, B, and C2
sites (Phe, Tyr, and Tyr, respectively), and the structure implies
a strong cation−π interaction between glutamate and TyrC2,
with perhaps a weaker one to TyrB (Figure 7).
Unnatural amino acid mutagenesis has been used to identify
cation−π interactions in GABAA and glycine receptors. In all
cases studied, such interactions have been localized to aromatic
residues on the principal face of the binding site, but the
residue(s) involved is surprisingly variable. In the GABAA
receptor comprising α1 and β2 subunits, the cation−π site for
GABA is TyrA (β2Tyr97),
68 while in the GABAA ρ1
homomeric receptor (also known as GABAC), the site is
TyrB (ρ1Tyr198).69 In the glycine receptor (α1 homomer) the
glycine cation−π site is PheB (α1Phe159).
70 In the above
examples the entire binding site was investigated, but only a
single cation−π site was found. However, in the insect GABA
RDL receptor, an anion-selective channel related to the
vertebrate GABAA receptors, GABA is bound by two cation−π
interactions: both PheB and TyrC2 are involved, consistent
with the GluCl structure.71
The variability of cation−π sites among GABA and glycine
receptors suggests that while the GluCl structure is no doubt a
valuable template for homology modeling, positioning of
agonists in the binding site is likely to vary. We also see that
the apparent strength of the cation−π interaction varies
considerably (Table 1). For cation−π interactions involving
Phe and Tyr, we consider the EC50 ratio of the
triﬂuorophenylalanine (F3-Phe) mutant to Phe as a measure
of cation−π strength. Among the GABA and glycine receptors,
Figure 6. Agonists of serotonin, GABA, and glycine receptors.
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estimated cation−π strengths range from a low of 2.1 kcal/mol
for TyrC2 with GABA at the insect RDL receptor71 to a high of
5.8 kcal/mol for GABA at TyrA of the α1, β2 GABAA receptor,
the strongest cation−π interaction we have characterized at any
Cys-loop receptor.68 Interestingly, variations in cation−π
strength are seen among diﬀerent agonists at the glycine
receptor (all of which bind to PheB): for glycine, the
interaction strength is 4.1 kcal/mol, while signiﬁcantly weaker
interactions of 2.4 and 1.8 kcal/mol are seen for the partial
agonists β-alanine and taurine, respectively (Table 1, Figure
6).72
Finally, there is one bona ﬁde pentameric receptor−agonist
complex captured by crystallography that has been functionally
interrogated by unnatural amino acid mutagenesis. The
prokaryotic receptor ELIC, a homologue of the eukaryotic
Cys loop receptors, was crystallized in complex with GABA.
The structure shows two cation−π interactions with phenyl-
alanines at the aromatic box B and C2 sites, and mutagenesis
conﬁrms both interactions. The stronger interaction properly
corresponds to the Phe closest to GABA’s ammonium group in
the structure.73
6. CONCLUSIONS
This work highlights the fruitful interplay between structural
studies of model systems and functional studies on full
mammalian receptors. There is no doubt that the structures
provide essential guidance as to possible key binding
interactions. However, extrapolating one structural model to
an entire family of receptors and to a wide range of agonists and
antagonists is not warranted. It will always be essential to probe
the real receptors to establish the essential binding features.
Along with providing crucial tests of predictions based on
structural information, the detailed binding interactions
revealed by unnatural amino acid mutagenesis present excellent
benchmarks for modeling studies that aim to reveal the origins
of subtype speciﬁcity.
Across the Cys loop family, we see that the details of ligand
binding (which interactions are present and which residues are
involved) vary across receptors and among diﬀerent ligands at
the same receptor. It has long been appreciated that closely
related receptors can have distinct pharmacologies, so these
diﬀerences should not be surprising. However, rationalizing
such distinctions across receptors is no easy task. Among the
closely related subtypes of the nAChR family, similar binding
sites engage agonists diﬀerently, and the diﬀerences become
more pronounced on moving to other members of the Cys-
loop receptor superfamily. Related binding sites must be shaped
diﬀerently, and extrapolations of ligand binding from one
receptor to another cannot readily be made. It is clear that
caution is warranted when extrapolating from model structures
to receptors of interest in human health.
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